Antengene Corporation Limited (HKG:6996)
Hong Kong · Delayed Price · Currency is HKD 4.780
-0.460 (-8.78%)
Aug 1, 2025, 4:08 PM HKT
Antengene Corporation Revenue
In the year 2024, Antengene Corporation had annual revenue of 91.95M CNY with 36.62% growth. Antengene Corporation had revenue of 31.17M in the half year ending December 31, 2024, a decrease of -70.64%.
Revenue
91.95M CNY
Revenue Growth
+36.62%
P/S Ratio
33.19
Revenue / Employee
544.08K CNY
Employees
169
Market Cap
3.25B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 91.95M | 24.65M | 36.62% |
| Dec 31, 2023 | 67.31M | -92.83M | -57.97% |
| Dec 31, 2022 | 160.14M | 131.37M | 456.62% |
| Dec 31, 2021 | 28.77M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| Akeso | 2.26B |
| Sino Biopharmaceutical | 30.72B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |